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THERAPY OF CANCER BY INSECT CELLS
CONTAINING RECOMBINANT
BACULOVIRUS ENCODING GENES
1.0 BACKGROUND OF THE INVENTION
1.1 Field of the Invention
The present invention relates generally to the fields of
immunology, cancer therapy, molecular biology and cell
biology. The present invention relates in particular to com-
positions and methods for use of insect cells containing
non-surface expressed proteins or peptides, encoded by
baculovirus expression vectors. Such compositions and
methods may be of therapeutic use in the treatment of
disease states, such as cancer.
1.2 Description of Related Art
Most progressively growing neoplasms do not provoke
immunological responses sufficient to control the growth of
malignant cells, despite the fact that tumor cells express
antigens which are recognizable as foreign by the immune
system of the patient (Sibille et al., 1990).
Tumor-associated antigens (TAAs) capable of being rec-
ognized by the cellular immune system (T-cells) have been
identified. These antigens (also referred to as tumor associ-
ated or T-cell epitopes) include oncogene products activated
by mutation and rearrangement(e.g., position 12 mutation in
p21’*; P210 product of ber/abl rearrangement); mutated
tumor-suppressor gene products (e.g., p53); reactivated
embryonic gene products not expressed in adult tissues (e.g.,
P91A found in the P815 mastocytoma); MAGE1 (found in
melanomas and human breast tumors); tissue specific self-
antigens expressed by tumors(e.g., tyrosinase); and a vari-
ety of others (Pardoll, 1993). Most tumorcell populations
express certain common TAAs,but are heterogeneous with
respect to the spectrum of TAAs that they express. Despite
the array of tumor-associated T-cell epitopes expressed in
tumors, tumor cells remain poorly immunogenic.
An approach to genetic engineering of tumorcells is the
use of viral expression vectors to infect tumorcells. Poxvi-
rus technology has been utilized to elicit immunological
responses to TAAs in animal models of experimentally-
induced tumors. The gene encoding carcinoembryonic anti-
gen (CEA) wasisolated from human colon tumorcells and
inserted into the vaccinia virus genome (Kaufman et al.,
1991). Inoculation of the vaccinia-based CEA recombinant
elicited CEA-specific antibodies and an antitumoreffect in
a mouse model(Id.). The human melanoma TAA, p97, has
also been inserted into vaccinia virus and shownto protect
mice from tumortransplants (Hu et al., 1988; Estin et al.,
1988). Bernards et al. (1987) constructed a vaccinia recom-
binant that expressed the extracellular domain of the neu-
encoded p185 glycoprotein. Mice immunized with this
recombinant virus developed a strong humoral response
against the neu gene product and were protected against
subsequent tumorchallenge.
Killing of tumor cells by the immune system is mediated
by cytotoxic T-lymphocytes (CTLs). However, the recogni-
tion of tumor-associated antigens is restricted by class 1
determinants specified by the major histocompatibility com-
plex (DeGiovanniet al., 1991; Porgadoret al., 1989; Kim et
al., 1994). Suppression or failure to express MHC class I
antigens is one of several documented mechanisms which
enable tumorcells to escape T-cell mediated host immunity
(Elliott et al., 1990; Tanaka et al., 1988).
Attempts have been madeto use cytokines to augmentthe
immune response to tumor-associated antigens. The goal of
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2
this strategy is to alter the local immunological environment
of the tumor cell to enhance the presentation of T-cell
epitopes or the activation of tumor-specific T-lymphocytes
(Pardoll, 1993). Various cytokine genes have been intro-
duced into tumor cells. Immunization with neoplastic cells
modified to secrete IL-2 (Porgadoret al., 1993a; Karpet al.,
1993), IFN-a (Porgadoret al., 1993b) or GM-CSF(Dranoff
et al., 1993), among others (Pardoll et al., 1992; Rosenberg
et al., 1992), resulted in the generation of CTLs with
cytotoxic activity towards both the cytokine-secreting and
non-secreting tumorcells. Experimental animals and a small
numberof patients with established neoplasmstreated with
the cytokine-secreting cells survived for prolonged periods,
although in most instances tumor growth eventually recurred
(id.).
Recombinant vaccinia viruses also have been used to
express cytokine genes (Ruby et al., 1992). Expression of
certain cytokines (IL-2, IFN-c) led to self-limiting vaccinia
virus infection in mice and, in essence,acted to attenuate the
virus. Expression of other cytokines (i.e. IL-5, IL-6) were
found to modulate the immune response to co-expressed
extrinsic immunogens (Review by Rubyel al., 1992).
Although promising, these observations have not yet
resulted in a clinically effective method of eliminating or
substantially reducing tumor burden in individuals with
cancer. In addition to being expensive,direct in vivo admin-
istration of purified cytokines may result in toxic side-
effects. Genetically engineering tumor cells to express
cytokines in vitro, with subsequent reintroduction into the
patient, is difficult, time-consuming, expensive and of
unprovenclinical efficacy. Gene therapy with human infec-
tive viruses engineered to express cytokineshas not yet been
successfully implementedat the clinical level. One difficulty
with this approach is the possible activation of replication-
defective viruses by in vivo recombination with naturally
occurring human viruses.
A potential solution to this problem involves using bacu-
lovirus that has been genetically engineered to express
therapeutic proteins. Naturally occurring insect baculovirus
infects only arthropods. The host range of insect baculovi-
ruses has been extensively studied and no evidence of
infection or pathogenic responses has been identified in
non-host insects, plants, vertebrates or humans (Groner,
1986). This feature may make baculovirus an ideal agentto
be modified and used for the delivery of drugs, genes, or
therapeutics.
2.0 SUMMARY OF THE INVENTION
The present invention addresses deficiencies in the art by
disclosing compositions and methodsfor use of insect cells
containing an isolated nucleic acid segment encoding a
selected non-surface expressed protein or peptide, for
example, a therapeutic protein. A “non-surface expressed
protein or peptide” is defined herein as an expressed protein
or peptide that is not localized to the cell membrane of the
insect cell. In this sense, such proteins or peptides may
potentially be secreted into the extracellular environment.
Alternatively, the non-surface expressed protein or peptide
may be intracellular within the insect cell.
In certain embodiments,the isolated nucleic acid segment
is contained within a baculovirus expression vector. The
construction of recombinant baculovirus vectors may be
accomplished by techniques well knownin theart.
In one aspect of the present invention, the non-surface
expressed protein or peptide is a cytokine. It is contemplated
that almost any cytokine could be used in the practice of the
US 6,342,216 B1
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present invention. Classes of cytokines contemplated within
the scope of the present invention include interferons,
interleukins, tumor necrosis factors and colony stimulating
factors. Examples of specific cytokines of potential use in
the present invention include interleukin 1 (IL-1), IL-2,
IL-5, IL-10, IL-11, IL-12, IL-18, interferon-y (IF-y), IF-a,
IF-6, tumor necrosis factors-a (TNF-a), and GM-CSF
(granulocyte macrophage colony stimulating factor). Such
examples are representative only and are not intended to
exclude other cytokines known in the art. In a particular
embodiment, the cytokine is B-interferon or GM-CSF.
The skilled artisan will realize that the term “protein or
peptide” encompassesproteins or peptides with the naturally
occurring amino acid sequences of identified proteins or
peptides, as well as minor sequencevariants of such proteins
or peptides. These may, for instance, be minor sequence
variants of the polypeptide which arise due to natural
variation within the population or they may be homologues
found in other species. They also may be sequences which
do not occur naturally but which are sufficiently similar that
they function similarly and/orelicit an immuneresponsethat
cross-reacts with natural forms of the polypeptide. Sequence
variants can be prepared by standard methods of site-
directed mutagenesis or peptide synthesis. Amino acid
sequence variants of the polypeptide can be substitutional,
insertional or deletion variants. Deletion variants lack one or
more residues of the native protein which are not essential
for function or immunogenic activity. A common type of
deletion variant is one lacking secretory signal sequences or
signal sequences directing a protein to bind to a particular
part of a cell.
Substitutional variants typically contain the exchange of
one amino acid for another at one or more sites within the
protein, and may be designed to modulate one or more
properties of the polypeptide such as stability against pro-
teolytic cleavage. Substitutions preferably are conservative,
that is, one aminoacid is replaced with one of similar shape
and charge. Conservative substitutions are well knownin the
art and include for example, the changes of: alanine to
serine; arginine to lysine; asparagine to glutamine orhisti-
dine; aspartate to glutamate; cysteine to serine: glutamine to
asparagine; glutamate to aspartate; glycine to proline; his-
tidine to asparagine or glutamine; isoleucine to leucine or
valine; leucine to valine or isoleucine; lysine to arginine,
glutamine, or glutamate; methionine to leucine or isoleu-
cine; phenylalanine to tyrosine, leucine or methionine;
serine to threonine; threonine to serine; tryptophan to
tyrosine; tyrosine to tryptophan or phenylalanine; and valine
to isoleucine or leucine.
Insertional variants include hybrid proteins containing
sequences from other proteins and polypeptides which are
homologues of the polypeptide. For example, an insertional
variant could include portions of the amino acid sequence of
the polypeptide from one species, together with portions of
the homologous polypeptide from another species. Other
insertional variants can include those in which additional
amino acids are introduced within the coding sequence of
the polypeptide. These typically are introduced, for
example, to disrupt a protease cleavagesite.
In one aspect, the invention is directed to a method of
providing a therapeutic protein to a mammal, comprising
preparing a composition comprising insect cells containing
an isolated nucleic acid segment encoding a selected non-
surface expressed protein or peptide and administering the
composition to a mammal. In a preferred embodiment, the
mammal is a human subject. In certain embodiments, the
insect cells are lyophilized or subjected to freeze-thaw
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cycles prior to administration. It is contemplated within the
scopeof the invention that administration of the composition
may be accomplished by essentially any route of
administration, such as intramuscular, subcutaneous,
intraperitoneal, intravascular or intraarterial. For an appro-
priate composition, administration may occur byoral, nasal,
buccal, rectal, vaginal or topical routes.
In a particular embodiment, the composition comprising
insect cells may be administered by direct intratumoral
injection to a mammal with cancer. The resulting activation
of the host immune system, targeted to one or more TAAs,
is of utility in reducing or eliminating tumor burden in the
subject. This surprising result is of great significance for the
clinical treatment of human cancer. Depending upon the
specific cytokine selected, other mechanismsof therapeutic
treatment are contemplated within the scope of the present
invention. For example, B-interferon may interfere with
tumor growth by inhibiting angiogenesis. (See Fabraet al.,
1992; Ghoji et al., 1994a, 1994b; Singh et al., 1995, 1996a,
1996b; Singh and Fidler, 1997; Dinneyet al., 1998, each of
which is incorporated herein by reference). In certain
embodiments, the administration of compositions compris-
ing insect cells may occur as an adjunct to or in combination
with more traditional tumor therapies, such as
chemotherapy, radiotherapy or immunotherapy.
The present invention further discloses the unexpected
result that subjects whose tumor burdens have been elimi-
nated are resistant to further challenge with cancers express-
ing the same TAA(s). Yet another surprising aspect of the
present invention is that direct tumoral injection of insect
cells alone may result in at least a partial suppression of
tumor growth. The possibility of an additive or synergistic
effect upon the host immune system of presenting both
insect cells and expressed therapeutic proteins is contem-
plated within the scope of the present invention.
The skilled artisan will realize that methods of therapeutic
treatment of cancer and methods of immunization of a
subject against recurrence of tumors exhibiting the same
TAA(s) are contemplated within the scope of the present
invention. It further is contemplated within the scope of the
present invention that insect cells expressing therapeutic
proteins may be used as universal adjuvants in boosting
immune system response in various other disease states,
such as AIDSor influenza. The skilled artisan will realize
that the term “insect cells” includes intactinsect cells as well
as insect cells that have been lyophilized or subjected to
freeze-thaw cycles.
One aspect of the present invention concerns composi-
tions comprising insect cells containing isolated nucleic acid
segments encoding a selected non-surface expressed protein
or peptide of interest. A variety of different types of insect
cells are considered within the scope of the present
invention, including cells from Autographa Californica
Bombyx mori, Spodoptera frugiperda, Choristoneura
fumiferana, Heliothis virescens, Heliothis zea, Orgyia
pseudotsugata, Lymantira dispar, Plutelia xylostella, Mala-
costoma disstria, Trichoplusia ni, Pieris rapae, Mamestra
configurata and Hyalophora cecropia. In a particular
embodiment, the insect cell is a Spodoptera frugiperda cell
or a Trichoplusia ni cell. In certain embodiments, such cells
may include Sf9 cells or H5 cells (High Five™, Invitrogen,
Sorrento, Calif.). In certain embodiments, the isolated
nucleic acid segment is incorporated into a baculovirus
expression vector.It is contemplated within the scope of the
present invention that the baculovirus may be any baculovi-
rus that can be engineered to express an isolated nucleic acid
segment encoding a selected non-surface expressed thera-
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peutic protein or peptide. Representative baculoviruses
include AcMNPV (Autographa californica multinucleo-
capsid nuclear polyhedrosis virus). BnNPV (Bombyx mori
nucleopolyhedrosis virus) and pBlueBac (Invitrogen,
Sorrento, Calif.). See U.S. Pat. No. 4,215,051 (incorporated
herein by reference).
Another embodiment of the present invention encom-
passes a kit for use in the therapeutic treatment of various
disease states, such as cancer, AIDS or influenza, said kit
comprising a pharmaceutical composition comprising insect
cells containing baculovirus. said baculovirus containing an
isolated nucleic acid segment encoding a selected non-
surface expressed therapeutic protein or peptide.
3.0 BRIEF DESCRIPTION OF THE DRAWINGS
This application contains at least one drawing executed in
color.
The following drawings form part of the present specifi-
cation and are included to further demonstrate certain
aspects of the present invention. The invention maybebetter
understood by reference to one or more of these drawings in
combination with the detailed description of specific
embodiments presented herein.
FIG.1. In vitro production of nitric oxide by macrophages
in response to stimulation by culture supernatants from H5
insect cells infected with baculovirus expressing IFN-f.
FIG.2A.In vitro production of nitric oxide by macroph-
ages in response to stimulation by sonicated lysates of H5
insect cells infected with baculovirus expressing IFN-f.
FIG. 2B. Lack of in vitro production of nitric oxide by
macrophages in response to sonicated lysates of control H5
insect cells without baculovirus.
FIG. 2C. Dose-response curve for in vitro production of
nitric oxide by macrophages as a function of IFN-B con-
centration in the supernatant fluids.
FIG.3. Effect of intratumoral injection of saline (control),
H5insect cells alone or H5 insect cells containing baculovi-
rus expressing IFN-B on tumor growth. UV-2237M fibro-
sarcomacells (2x10°/mouse) were injected subcutaneously
(s.c.) into syngeneic C3H/HeN mice. Nine days later the
mice were treated by intratumoral injection. H5 cells with
baculovirus encoding IFN-f were prepared by infection with
50 ul of baculovirus for 24 hours in T150 flasks.
FIG.4. A repeat of the study shown in FIG.3, with n=10
mice.
FIG.5. Effect of intratumoral injectionoflive, lyophilized
and freeze-thawed H5 insect cells containing baculovirus
expressing IFN-B on tumor growth of UV-2237M fibrosar-
comacells injected s.c. into C3H/HeN mice (n=10).
FIG.6. Generation of systemic immunity in mice “cured”
of UV-2237M tumors by intratumoral injection of lyo-
philized H5 insect cells containing baculovirus expressing
IFN-$. C3H/HeN mice (n=10) were injected s.c. with
UV-2237M cells. A single intratumorial injection was
administered to tumors of 5-6 mm in diameter. Six weeks
after tumor regression, the mice were challenged by injec-
tion of the indicated amounts of new UV-2237Mcells. All
control mice developed tumors, while none of the “cured”
mice developed tumors.
FIG. 7. Systemic immunity in mice “cured” of subcuta-
neous UV-2237M tumors by intratumoral injection of lyo-
philized H5 insect cells containing baculovirus expressing
IFN-£ is specific to tumor type. Mice “cured” of subcuta-
neous UV-2237M tumors as described in the legend to FIG.
6 were challenged by injection of the indicated amounts of
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the syngeneic, non-cross-reactive K-1735 melanoma cell
line. Both control and “cured” mice developed tumors.
FIG. 8. Immunohistochemistry of regressing UV-2237M
s.c. tumors.
4.0 DESCRIPTION OF ILLUSTRATIVE
EMBODIMENTS
A number of disease states, such as cancer may in
principle be treated by manipulation of the host immune
response to the disease (e.g., Xie et al., 1997; Donget al.,
1998, 1999). In practice, deficiencies in the art exist with
respect to an effective method for manipulating host immune
response. The present invention addresses these deficiencies
by providing compositions and methods of use of insect
cells comprising baculovirus encoding therapeutic, non-
surface expressed proteins or peptides. More particularly,
the present invention relates to administering therapeutically
effective amounts of such insect cells expressing such pro-
teins or peptides to subjects with disease states such as
cancer. In certain embodiments of the present invention, the
proteins or peptides are cytokines.
The present invention also concerns methods of inducing
tumor regression following administration of insect cells
containing non-surface expressed proteins or peptides, for
example, cytokines. Another aspect of the present invention
concerns methods of preventing the recurrence of cancer in
subjects who have been administered such insect cells
expressing such proteins or peptides.
4.1 Insect Cells
The term “insect cells” means insect cells from the insect
species which are subject to baculovirus infection. For
example: Autographa californica, Bombyx mori,
Spodoptera frugiperda, Choristoneura fumiferana, Helio-
this virescens, Heliothis zea, Orgyia pseudotsugata, Lyman-
tira dispar, Plutelia xylostella, Malacostoma disstria, Tri-
choplusia ni, Pieris rapae, Mamestra configurata and
Hyalophora cecropia. See U.S. Pat. Nos. 5,498,540 and
5,759,809, incorporated herein by reference. In a particular
embodiment, the insect cells are H5 insect cells (Invitrogen,
Sorrento, Calif.), derived from Trichoplusia ni. Such insect
cells may be used in an intact form, or may be used
following lyophilization or freeze-thaw cycles.
Insect cells may be cultured according to standard
techniques, such as in IPL-41 medium (JRH Biosciences,
Inc.) containing 10% fetal calf serum (Hyclone
Laboratories, Inc.) as described in U.S. Pat. No. 5,759,809.
An alternative procedure for culturing insect cells in media
containing fish serum has recently been described. See U.S.
Pat. No. 5,498,540, incorporated herein by reference. Cul-
tured insect cells may be transfected with recombinant
baculovirus by standard protocols. See, e.g., U.S. Pat. No.
5,759,809, incorporated herein by reference.
4.2 Isolated Nucleic Acid Segments Encoding
Cytokines
In various embodiments of the present invention, the
insect cells contain isolated nucleic acid segments encoding
the production of therapeutic proteins or peptides. Proteins
or peptides useful in the application of the present invention
include those known as cytokines. Table 1 below provides a
listing of cytokines that may beofutility in the practice of
the present invention.
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TABLE1 TABLE 2
Cytokines Amino Acids Codons
IL-1 IL-2 IL-3 IL-4 5 Alanine Ala A GCA GCC GCG GCU
IL-5 IL-6 IL-7 IL-8 Cysteine Cys Cc UGC UGUIL-9 IL-10 IL-11 IL-12 Aspartic acid Asp D GAC GAU
IL-13 IL-14 IL-15 f-interferon Glutamic acid Glu E GAAGAG
a-interferon angiostatin  thrombospondin endostatin Phenylalanine Phe F UUC UUU
METH-1 METH-2 GM-CSF G-CSF Glycine Gly G  GGAGGC GGG GGU
10 Histidine His H CAC CAU
Isoleucine Tle I AUAAUC AUU
: : : Lysine Lys K AAAAAGThe DNA and amino acid sequences of the above-listed Leucine Leu L  UUAUUG CUA CUC CUG CUU
proteins or peptides may be obtained from sources well Methionine Met M AUG
known to those of skill in the art, including GenBank. Asparagine Asn N AAC AAUIsolated lei id di f th teins listed 45 Proline Pro P CCA CCC CCG CCUsolated nucleic acids encoding many of the proteinsliste Glutamine Gin Q CAACAG
above maybe obtained in the form of pre-existing vectors Arginine Arg R  AGAAGG CGA CGC CGG CGU
from standard sources, such as the American Type Culture Serine ; er ° nenenCGCu UCG UCU
. . * reonine rCollection (ATCC, Gaithersburg, Md.). Alternatively, syn- Valine Val Vv GUA GUC GUG GuU
thetic genes encoding the proteins or peptides of interest 59 Tryptophan Trp Ww UGG
may be chemically synthesized by methods well known in Tyrosine Tyr Y UAC UAU
the art, such as on commercially available automated oli-
gonucleotide synthesizers.
As discussed below, a gene encoding a selected therapeu-
tic protein may contain a variety of different bases and yet
still produce a corresponding polypeptide that is indistin-
guishable functionally, and in somecasesstructurally, from
the naturally occurring gene product.
Any reference to an isolated nucleic acid should be read
as encompassing a host cell containing that nucleic acid and
capable of expressing the product of that nucleic acid.
Nucleic acids accordingto the present invention may encode
an entire gene, a domain of a therapeutic protein, or any
other fragment of the protein sequence. The nucleic acid
may be derived from genomic DNA,ie., cloned directly
from the genome of a particular organism. In preferred
embodiments, however, the nucleic acid would comprise
complementary DNA (cDNA). Also contemplated is a
cDNAplusa natural intron or an intron derived from another
gene. Such engineered molecules are sometime referred to
as “mini-genes.”
The term “cDNA”is intended to refer to DNA prepared
using messenger RNA (mRNA)as template. The advantage
of using a cDNA, as opposed to genomic DNA or DNA
polymerized from a genomic, non- or partially-processed
RNAtemplate, is that the cDNA primarily contains coding
sequences of the corresponding protein. There may be times
whenthe full or partial genomic sequenceis preferred, such
as where the non-coding regions are required for optimal
expression.
It also is contemplated that therapeutic proteins may be
represented by natural variants that have slightly different
nucleic acid sequences but, nonetheless, encode the same
proteins (see Table 2 below).
As used in this application, the term “an isolated nucleic
acid segment encoding a non-surface expressed protein or
peptide” refers to a nucleic acid molecule that has been
isolated free of total cellular nucleic acid. The term “func-
tionally equivalent codon”is used herein to refer to codons
that encode the same amino acid, such as the six codons for
arginine or serine (Table 2, below), and also refers to codons
that encode biologically equivalent amino acids, as dis-
cussed in the following pages.
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The DNA segments of the present invention include those
encoding biologically functional equivalent non-surface
expressed proteins and peptides. Such sequences may arise
as a consequence of codon redundancy and amino acid
functional equivalency that are known to occur naturally
within nucleic acid sequences andthe proteins thus encoded.
Alternatively, functionally equivalent proteins or peptides
may be created via the application of recombinant DNA
technology, in which changesin the protein structure may be
engineered, based on considerations of the properties of the
amino acids being exchanged. Changes designed by man
may be introduced through the application of site-directed
mutagenesis techniques or may be introduced randomly and
screened later for the desired function.
4.3 Infection with Baculoviral Vectors
In certain embodiments of the invention, the nucleic acid
encoding a selected non-surface expressed protein or peptide
maybe integrated into a baculovirus expression vector. Such
vectors are useful tools for the production of proteins for a
variety of applications (Summers and Smith, 1987; O’Reilly
et al., 1992; also U.S. Pat. No. 4,745,051 (Smith and
Summers), U.S. Pat. No. 4,879,236 (Smith and Summers),
USS. Pat. No. 5,077,214 (Guarino and Jarvis), U.S. Pat. No.
5,155,037 (Summers), U.S. Pat. No. 5,162,222, (Guarino
and Jarvis), U.S. Pat. No. 5,169,784 (Summers and Oker-
Blom) and USS. Pat. No. 5,278,050 (Summers), each incor-
porated herein by reference). Baculovirus expression vectors
are recombinantinsect vectors in which the coding region of
a particular gene of interest is placed behind a promoter in
place of a nonessential baculoviral gene. The classic
approach used to isolate a recombinant baculovirus expres-
sion vector is to construct a plasmid in which the foreign
gene of interest is positioned downstream of the polyhedrin
promoter. Then, via homologous recombination, that plas-
mid can be used to transfer the new gene into the viral
genomein place of the wild-type polyhedrin gene (Summers
and Smith, 1987; O’Reilly et al., 1992).
The resulting recombinantvirus can infect cultured insect
cells and express the foreign gene under the control of the
polyhedrin promoter, whichis strong and provides very high
levels of transcription during the very late phase of infection.
The strength of the polyhedrin promoteris an advantage of
the use of recombinant baculoviruses as expression vectors
becauseit usually leads to the synthesis of large amounts of
the foreign gene product during infection.
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Autographa californica multinucleocapsid nuclear poly-
hedrosis virus (ACMNPV)is unusual among baculoviruses
because it displays a wider host range than most baculovi-
ruses (Martignoni et al., 1982). AcCMNPV is the most
extensively studied baculovirus and its genome sequenceis
known(Ayreset al., 1994). It is distinguished by a unique
biphasic life cycle in its lepidopteran host insect (reviewed
in Blissard and Rohrmann, 1990). Infection produces high
titers of two forms of progeny virus, budded virus (BV) and
occlusion derived virus (ODV).
Two routes, adsorptive endocytosis (or viropexis) and
direct fusion of BV envelope with plasma membrane, are
proposed for entry of BV into cultured cells. Although BV
may enter cells by fusion (Volkman et al., 1986; Kozuma
and Hukuhara, 1994), the majority of data indicates that the
primary route is by adsorptive endocytosis (Charlton and
Volkman, 1993).
4.3.1 Expression of Cloned Genes from Baculovirus Pro-
moters and Enhancers
In certain aspects of the present invention, baculovirus
vectors which are designed for the expression of a desired
gene or genes are required. Thus, particular embodiments
may require a selected nucleic acid segment to be operably
linked to control sequences, such as promoters and enhanc-
ers. In the context of positioning nucleic acid segments and
sequence regions in combination, the term “operably linked”
will be understood to mean connected so as to form asingle,
contiguous nucleic acid sequence, wherein the promoters,
enhancers and other control sequences are positioned and
oriented in a manner to provide optimal expression of the
gene. It will be understood that promoters are DNAelements
which when positioned functionally upstream of a gene
leads to the expression of that gene. Each heterologous gene
in the vector of the present invention is functionally posi-
tioned downstream of a promoter element.
In transient systems, the geneofinterest is introduced into
the cell by infection with a recombinantvirus, for example
baculovirus. In the most widely used baculovirus systems,
the gene of interest is under the control of the polyhedrin
promoter. The polyhedrin promoteris a very late promoter,
which meansthat the expression of the gene of interest does
notstart until the late phase of the baculovirus infection. The
expression levels are high, but transient as the baculovirus
infection eventually leads to cell death.
4.3.2 Baculoviral Promoters and Enhancers
There are four distinct phases of a baculovirus infection,
termed immediate-early, delayed-early, late and very late.
Therefore, different baculovirus genes may be classified
according to the phase of the viral infection during which
they are expressed. Also there are a class of genes which
have been defined as early genes, which have not been
subcatagorized as either immediate-early or delayed-early.
Different classes of promoters control each class of gene.
Immediate early promoters are distinguished by needing
only host cell factors to drive expression. Examples are the
iel (Guarino and Summers, 1987), ieN (ie2; Carson et al.,
1991) and ieO promoters.
Delayed early promoters are distinguished by needing
only products of the immediate-early genes, in addition to
host cell factors to drive expression. Examples are the 39K
(Guarino and Smith, 1991) and gp64 (Blissard and
Rohrmann, 1989; Whitford et al., 1989) promoters.
Early promoters have not been placed into the specific
immediate-early of delayed-early class. Examples include
the DA26, ETL and 35K promoters.
Late promoters requires products of the delayed-early and
immediate-early genes, as well as other host cell factors, to
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drive expression. Examples are the gp64 (Blissard and
Rohrmann, 1989; Whitford et al., 1989) and capsid (p39,
Thiem and Miller, 1989) promoters.
Very late promoters requires a number of baculovirus
gene products, in addition to other host cell factors, to drive
expression. Examples of promoters from this class are the
polyhedrin (Hooft van Iddekingeet al., 1983) and the p10
(Kuzio et al., 1984) promoters. The best characterized and
most often used baculoviral promoter is the polyhedrin
promoter. The use of the polyhedrin promoteris a preferred
embodiment of the present invention.
Enhancers are DNA elements which can bepositionally
located to enhance transcription from a given promoter.
Enhancers whichare active in insectcells to drive transcrip-
tion are preferred in the present invention. Preferred are viral
enhancers, and most preferred are baculoviral enhancers.
Examples of baculoviral enhancers includehr1, hr2, hr3, hr4
and hr5 (Guarinoet al., 1986).
4.4 Marker Genes and Screening
In certain aspects of the present invention, specific cells
may be tagged with specific genetic markers to provide
information about the infected, transduced or transformed
cells. Fherefore, the present invention also provides recom-
binant candidate screening and selection methods which are
based upon whole cell assays and which,preferably, employ
a reporter gene that confers on its recombinant hosts a
readily detectable phenotype that emerges only under con-
ditions where a general DNA promoterpositioned upstream
of the reporter gene is functional. Generally, reporter genes
encode a polypeptide (marker protein) not otherwise pro-
duced by the host cell which is detectable by analysis of the
cell culture, e.g., by fluorometric, radioisotopic or spectro-
photometric analysis of the cell culture.
In other aspects of the present invention, a genetic marker
is provided whichis detectable by standard genetic analysis
techniques, such as DNA amplification by PCR™or hybrid-
ization using fluorometric, radioisotopic or spectrophoto-
metric probes.
Exemplary marker genes encode enzymes such as
esterases, phosphatases, proteases (tissue plasminogen acti-
vator or urokinase) and other enzymes capable of being
detected by their activity, as will be knownto those skilled
in the art. Contemplated for use in the present invention is
green fluorescent protein (GFP) as a marker for transgene
expression (Chalfie et al., 1994). The use of GFP does not
need exogenously added substrates, only irradiation by near
UVorbluelight, and thus has significant potential for use in
monitoring gene expression in living cells.
Other examples are chloramphenicol acetyltransferase
(CAT) which may be employed with a radiolabeled
substrate, firefly and bacterial luciferase, and the bacterial
enzymes(-galactosidase and f}-glucuronidase. Other marker
genes within this class are well knownto those of skill in the
art, and are suitable for use in the present invention.
Another class of marker genes which confer detectable
characteristics on a host cell are those which encode
polypeptides, generally enzymes, which render their trans-
formants resistant against toxins. Examplesofthis class of
marker genes are the neo gene (Colberre-Garapin et al.,
1981) which protects against toxic levels of the antibiotic
G418, the gene conferring streptomycin resistance (U'S. Pat.
No. 4,430,434), the gene conferring hygromycin B resis-
tance (Santerre et al., 1984; U.S. Pat. Nos. 4,727,028,
4,960,704 and 4,559,302) a gene encoding dihydrofolate
reductase, which confers resistance to methotrexate (Alt et
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al., 1978) and the enzyme HPRT, along with many others
well known in the art (Kaufman, 1990).
4.5 Pharmaceutical Compositions and Routes of
Administration
Whereclinical applications are contemplated, it will be
necessary to prepare pharmaceutical compositions of the
peptides, proteins, nucleic acids, viruses and cells in a form
appropriate for the intended application. Generally, this will
entail preparing compositions that are essentially free of
endotoxins, as well as other impurities that could be harmful
to humansor animals.
Onewill generally desire to employ appropriate salts and
buffers to render peptides, proteins, nucleic acids, viruses or
cells suitable for introduction into a patient. Aqueous com-
positions of the present invention comprise an effective
amountof peptides, proteins, nucleic acids, virusesorcells,
dissolved or dispersed in a pharmaceutically acceptable
carrier or aqueous medium, and preferably encapsulated.
The phrase “pharmaceutically or pharmacologically accept-
able” refer to molecular entities and compositions that do
not produce adverse, allergic, or other untoward reactions
when administered to an animal or a human.As used herein,
“pharmaceutically acceptable carrier” includes any andall
solvents, dispersion media, coatings, antibacterial and anti-
fungal agents, isotonic and absorption delaying agents and
the like. The use of such media and agents for pharmaceu-
tically active substances is well know in the art. Except
insofar as any conventional media or agent is incompatible
with the vectors or cells of the present invention, its use in
therapeutic compositions is contemplated. Supplementary
active ingredients, such as other anti-cancer agents, can also
be incorporated into the compositions.
Solutions of the active ingredients as free base or phar-
macologically acceptable salts can be prepared in water
suitably mixed with surfactant, such as hydroxypropylcel-
lulose. Dispersions also can be prepared in glycerol, liquid
polyethylene glycols, mixtures thereof and in oils. Under
ordinary conditions of storage and use, these preparations
contain a preservative to prevent growth of microorganisms.
Intravenous vehicles include fluid and nutrient replenishers.
Preservatives include antimicrobial agents, anti-oxidants,
chelating agents and inert gases. The pH and exact concen-
tration of the various components in the pharmaceutical are
adjusted according to well-known parameters.
An effective amount of the peptides, proteins, nucleic
acids, viruses or cells is determined based on the intended
goal. The term “unit dose” refers to a physically discrete unit
suitable for use in a subject, each unit containing a prede-
termined quantity of the therapeutic composition calculated
to produce the desired response in association with its
administration, i.e., the appropriate route and treatment
regimen. The quantity to be administered, both according to
numberof treatments and unit dose, depends on the subject
to be treated, the state of the subject, and the protection
desired. Precise amounts of the therapeutic composition also
depend on the judgmentof the practitioner and are peculiar
to each individual.
Guidance on the amountof insect cells containing bacu-
lovirus to inject into tumors is provided in the Examples
below. In general, a dose of 1x10° cells per tumor was
injected into tumors of 5-6 mm insize. It is expected that the
dosage for tumor injection will be determined more by the
mass of the tumor than by the size of the patient. Thus, a
standard dosage for injection into a 5-6 mm tumor in
humans might be approximately 1x10°cells. In the case of
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injection of cells that have been disrupted by freeze-thaw
cycles, injection of an amount of protein equivalent to a
dosage of 1x10° cells would be appropriate for a 5-6 mm
tumor.
Alternatively, the amount of composition to be adminis-
tered may be determined by the skilled artisan based upon
the concentration of active protein in the composition. The
concentration of active protein may be determined by means
well known in the art, such as bioassay or by direct mea-
surement of the quantity of specific proteins. (See Reming-
ton’s Pharmaceutical Sciences, 18th Ed., 1990). Direct mea-
surement of specific proteins may be accomplished by
techniques well knownin the art, such as ELISA or Western
blotting.
The amountof active protein to be administered will vary
for the specific protein of interest. For example, dosages of
interferon-c to administer to a human subject range from
3x10° IU to 3x10° IU. (See Remington’s Pharmaceutical
Sciences, 18th Ed., 1990). Standard dosages for interleukin
2 have been reported as 30,000 to 300,000 U/kg/day. (Id.)
Standard dosages for other therapeutic proteins are well
knownin theart.
4.5.1 Parenteral Administration
The active compoundsof the present invention will often
be formulated for parenteral administration, e.g., formulated
for injection via the intravenous, intramuscular,
subcutaneous, or even intraperitoneal routes. The prepara-
tion of an aqueous composition that contains a second
agent(s) as active ingredients will be knownto those ofskill
in the art in light of the present disclosure. Typically, such
compositions can be prepared as injectables, either as liquid
solutions or suspensions; solid forms suitable for using to
prepare solutions or suspensions upon the addition of a
liquid prior to injection can also be prepared; and the
preparations can also be emulsified.
Solutions of the active compoundsas free base or phar-
macologically acceptable salts can be prepared in water
suitably mixed with a surfactant, such as hydroxypropylcel-
lulose. Dispersions can also be prepared in glycerol, liquid
polyethylene glycols, and mixtures thereof and in oils.
Under ordinary conditions of storage and use, these prepa-
rations contain a preservative to prevent the growth of
microorganisms.
The pharmaceutical forms suitable for injectable use
include sterile aqueous solutions or dispersions; formula-
tions including sesameoil, peanut oil or aqueous propylene
glycol; and sterile powders for the extemporaneous prepa-
ration of sterile injectable solutions or dispersions. In all
cases the form mustbesterile and mustbefluid to the extent
that easy syringability exists. It must be stable under the
conditions of manufacture and storage and must be pre-
served against the contaminating action of microorganisms,
such as bacteria and fungi.
The active compounds may be formulated into a compo-
sition in a neutral or salt form. Pharmaceutically acceptable
salts, include the acid addition salts (formed with the free
amino groups of the protein) and which are formed with
inorganic acids such as, for example, hydrochloric or phos-
phoric acids, or such organic acids as acetic, oxalic,tartaric,
mandelic, and the like. Salts formed with the free carboxyl
groups can also be derived from inorganic bases such as, for
example, sodium, potassium, ammonium,calcium,or ferric
hydroxides, and such organic bases as isopropylamine,
trimethylamine, histidine, procaine and the like.
The carrier can also be a solvent or dispersion medium
containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol,
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and the like), suitable mixtures thereof, and vegetable oils.
The proper fluidity can be maintained, for example, by the
use of a coating, such as lecithin, by the maintenance of the
required particle size in the case of dispersion and by the use
of surfactants. The prevention of the action of microorgan-
isms can be brought about by various antibacterial ad
antifungal agents, for example, parabens, chlorobutanol,
phenol, sorbic acid, thimerosal, and the like. In many cases,
it will be preferable to include isotonic agents, for example,
sugars or sodium chloride. Prolonged absorption of the
injectable compositions can be brought about by the use in
the compositions of agents delaying absorption, for
example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating
the active compoundsin the required amountin the appro-
priate solvent with various of the other ingredients enumer-
ated above, as required, followed by filtered sterilization.
Generally, dispersions are prepared by incorporating the
various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium and the
required other ingredients from those enumerated above.In
the case of sterile powders for the preparation of sterile
injectable solutions, the particular methods of preparation
are vacuum-drying and freeze-drying techniques which
yield a powderof the active ingredient plus any additional
desired ingredient from a previously sterile-filtered solution
thereof.
For parenteral administration in an aqueoussolution, for
example, the solution should be suitably buffered if neces-
sary and the liquid diluent first rendered isotonic with
sufficient saline or glucose. These particular aqueous solu-
tions are especially suitable for intravenous, intramuscular,
subcutaneous and intraperitoneal administration. In this
connection, sterile aqueous media which can be employed
will be known to those of skill in the art in light of the
present disclosure. For example, one dosage could be dis-
solved in 1 ml of isotonic NaClsolution and either added to
1000 ml of hypodcrmoclysis fluid or injected at the proposed
site of infusion, (see for example, Remington’s Pharmaceu-
tical Sciences, 18th Edition, 1990). Some variation in dos-
age will necessarily occur depending on the condition of the
subject being treated. The person responsible for adminis-
tration will, in any event, determine the appropriate dose for
the individual subject.
4.5.2 Other Routes of Administration
In addition to the compounds formulated for parenteral
administration, such as intravenous or intramuscular
injection, other pharmaceutically acceptable forms include,
e.g., tablets or other solids for oral administration; time
release capsules; and any other form currently used, includ-
ing cremes, lotions, mouthwashes, inhalants and the like.
The compositions of the present invention may include
classic pharmaceutical preparations. Administration of these
compositions according to the present invention will be via
any commonroute so longas the target tissue is available via
that route. This includesoral, nasal, buccal, rectal, vaginal or
topical. Alternatively, administration may be by orthotopic,
intradermal, subcutaneous, intramuscular, intraperitoneal or
intravenousinjection. The injection can be general, regional,
local or direct injection, for example, of a tumor. Also
contemplated is injection of a resected tumor bed, and
continuousperfusion via catheter. Such compositions would
normally be administered as pharmaceutically acceptable
compositions, described supra.
The compositions of the present invention are advanta-
geously administered in the form of injectable compositions
either as liquid solutions or suspensions; solid forms suitable
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for solution in, or suspensionin,liquid prior to injection also
may be prepared. These preparations also may be emulsi-
fied. A typical composition for such purposes comprises a 50
mg or up to about 100 mg of human serum albumin per
milliliter of phosphate buffered saline. Other pharmaceuti-
cally acceptable carriers include aqueous solutions, non-
toxic excipients including salts, preservatives, buffers and
the like. Examples of non-aqueous solvents are propylene
glycol, polyethylene glycol, vegetable oil and injectable
organic esters, such as theyloleate. Aqueouscarriers include
water, alcoholic/aqueous solutions saline solutions,
parenteral vehicles such as sodium chloride, Ringer’s
dextrose, etc. Intravenous vehicles include fluid and nutrient
replenishers. Preservatives include antimicrobial agents,
anti-oxidants, chelating agents and inert gases. The pH and
exact concentration of the various components in the phar-
maceutical are adjusted according to well known param-
eters.
Additional formulations are suitable for oral administra-
tion. Oral formulations include such typical excipients as,
for example, pharmaceutical grades of mannitol, lactose,
starch, magnesium stearate, sodium saccharine, cellulose,
magnesium carbonate and the like. The compositions take
the form of solutions, suspensions, tablets, pills, capsules,
sustained release formulations or powders. When the route
is topical, the form may be a cream,ointment, salve or spray.
An effective amount of the therapeutic agent is deter-
mined based on the intended goal. The term “unit dose”
refers to a physically discrete unit suitable for use in a
subject, each unit containing a predetermined quantity of the
therapeutic composition calculated to produce the desired
response in association with its administration, ie., the
appropriate route and treatment regimen. The quantity to be
administered, both according to number of treatments and
unit dose, depends on the subject to be treated, the state of
the subject and the protection desired. Precise amounts of
the therapeutic composition also depend on the judgmentof
the practitioner and are peculiar to each individual.
In certain cases, the therapeutic formulations of the inven-
tion could also be prepared in forms suitable for topical
administration, such as in cremes and lotions. These forms
may be used for treating skin-associated diseases, such as
various sarcomas.
Upon formulation, solutions will be administered in a
manner compatible with the dosage formulation and in such
amountas is therapeutically effective. The formulations are
easily administered in a variety of dosage forms, such as the
type of injectable solutions described above, with even drug
release capsules and the like being employable.
4.6 Combined Therapy with Immunotherapy,
Chemotherapy, Biological Therapy or Radiotherapy
It is contemplated that a variety of tumors mightbe treated
within the scope of the present invention, including but not
limited to cancers of the skin, head, neck, brain, mouth
esophagus, stomach, intestines, rectum, vagina, ovaries,
cervix, uterus, prostate, testes, breast, lungs, liver, spleen,
pancreas, kidneys, bladder, lymphatic system, blood, bone
and muscle. Treatmentof types of tumorsthat are considered
within the scope of the present invention include but are not
limited to sarcomas, adenomas, carcinomas, adenocarcino-
mas lymphomas, Hodgkin’s disease, ncuroblastomas,
rhabdomyosarcomas, retinoblastomas, myelomas,
melanomas, insulinomas, leukemias and other neoplasias.
Tumorcell resistance to DNAdamaging agents represents
a major problem in clinical oncology. One goal of current
cancer research is to find ways to improve the efficacy of
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chemotherapy and radiotherapy. One way is by combining
such traditional therapies with novel therapies, such as the
methods of the present invention. In the context of the
present invention, it is contemplated that administration of
compositions comprising insect cells, with or without bacu-
lovirus encoding therapeutic proteins (“insect cell
composition”), could potentially be used in conjunction with
chemo- or radiotherapeutic intervention.
To kill cells, inhibit cell growth, inhibit metastasis, inhibit
angiogenesis or otherwise reverse or reduce the malignant
phenotype of tumor cells, using the methods and composi-
tions of the present invention, one might contact a “target”
cell with an insect cell composition and at least one other
agent. These treatments would be provided in a combined
amount effective to kill or inhibit proliferation of the cell.
This process may involve contacting the cells with the insect
cell composition and the other agent(s) or factor(s) at the
same time. This may be achieved by contacting the cell with
a single composition or pharmacological formulation that
includes both agents, or by contacting the cell with two
distinct compositions or formulations simultaneously,
wherein one composition includes the insect cell composi-
tion and the other includes the agent.
Alternatively, the insect cell composition treatment may
precede or follow the other agent treatment by intervals
ranging from min to wk. In such embodiments, one would
generally ensure that a significant period of time did not
expire between the time of each delivery, such that the agent
and insect cell composition would still be able to exert an
advantageously combined (e.g., synergistic) effect on the
target cell. In such instances, it is contemplated that one
would contact the cell with both modalities within about
12-24 h of each other and, more preferably, within about
6-12 h of each other, with a delay time of only about 12 h
being most preferred. In somesituations, it may be desirable
to extend the duration of treatment with only the therapeutic
agent significantly, for example, where several days (2,3,4,
5, 6 or 7) to several wk(1, 2, 3, 4,5, 6, 7 or 8) lapse between
the respective administrations.
It also is conceivable that more than one administration of
either insect cell composition or the other agent will be
desired. Various combinations may be employed, where
insect cell composition is “A” and the other agent is “B”, as
exemplified below:
A/B/A B/A/B B/B/AA/A/B B/A/A A/B/B B/B/B/A B/B/
A/B
A/A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B
B/B/B/A
A/A/A/B B/A/A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B
B/B/A/B
To achieve cell killing, both agents are deliveredto a cell
in a combined amounteffective to kill the cell.
Agents or factors suitable for use in a combined therapy
are any chemical compound or treatment method that
induces DNA damage when applied to a cell. Such agents
and factors include radiation and waves that induce DNA
damage such as y-irradiation, X-rays, UV-irradiation,
microwaves, electronic emissions, and the like. A variety of
chemical compounds, also described as “chemotherapeutic
agents,” function to induce DNA damage,all of which are
intended to be of use in the combined treatment methods
disclosed herein. Chemotherapeuticagents contemplated to
be of use include, e.g., adriamycin. 5-fluorouracil (SFU),
etoposide (VP-16) camptothecin, actinomycin-D, mitomy-
cin C, cisplatin (CDDP) and even hydrogen peroxide. The
invention also encompassesthe use of a combination of one
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or more DNA damaging agents, whether radiation-based or
actual compounds,such as the use of X-rays with cisplatin
or the use of cisplatin with etoposide.
In treating cancer according to the invention, one would
contact the tumorcells with an agent in addition to the insect
cell composition. This may be achieved by irradiating the
localized tumorsite with radiation such as X-rays, UV-light,
y-rays or even microwaves. Alternatively, the tumor cells
may be contacted with the agent by administering to the
subject a therapeutically effective amount of a pharmaceu-
tical composition comprising a compound such as,
adriamycin, 5-fluorouracil, etoposide, camptothecin,
actinomycin-D, or mitomycin C. The agent may be prepared
and used as a combined therapeutic composition, or kit, by
combining it with the insect cell composition, as described
above.
Agents that directly cross-link nucleic acids, specifically
DNA,are envisaged to facilitate DNA damage leading to a
synergistic, antineoplastic combination with insect cell com-
positions. Agents such as cisplatin, and other DNA alkylat-
ing agents may be used.
Agents that damage DNAalso include compoundsthat
interfere with DNAreplication, mitosis and chromosomal
segregation. Such chemotherapeutic compounds include
adriamycin, also known as doxorubicin, etoposide,
verapamil, podophyllotoxin, and the like. Widely used in a
clinical setting for the treatment of neoplasms, these com-
pounds are administered intravenouslythrough bolus injec-
tions at doses ranging from 25—75 mg/m”at 21 dayintervals
for adriamycin, to 35-50 mg/m?for etoposideintravenously
or double the intravenous dose orally.
Agents that disrupt the synthesis and fidelity of nucleic
acid precursors and subunits also lead to DNA damage. A
number of nucleic acid precursors have been developed for
this purpose. Particularly useful are agents that have under-
gone extensive testing and are readily available, such as
5-fluorouracil (5-FU). Although quite toxic, 5-FU is appli-
cable in a wide rangeofcarriers, including topical. However
intravenous administration with doses ranging from 3 to 15
mg/kg/day is commonly used.
Other factors that cause DNAdamageand have been used
extensively include y-rays, X-rays, and/or the directed deliv-
ery of radioisotopes to tumor cells. Other forms of DNA
damagingfactors also are contemplated such as microwaves
and UV-irradiation. It is most likely that all of these factors
effect a broad range of damage to DNA,onthe precursors of
DNA,the replication and repair of DNA, and the assembly
and maintenance of chromosomes. Dosage ranges for
X-rays range from daily doses of 50 to 200 roentgens for
prolonged periods of time (3 to 4 wk), to single doses of
2000 to 6000 roentgens. Dosage ranges for radioisotopes
vary widely, and depend on the half-life of the isotope, the
strength and type of radiation emitted, and the uptake by the
neoplastic cells.
The skilled artisan is directed to “Remington’s Pharma-
ceutical Sciences” 18th Edition (1990). Some variation in
dosage will necessarily occur depending on the condition of
the subject being treated. The person responsible for admin-
istration will, in any event, determine the appropriate dose
for the individual subject. Moreover, for human
administration, preparations should meetsterility, toxicity,
and general safety and purity standards as required by the
FDAOffice of Biologics standards.
The regional delivery of insect cell compositions to
patients with prostate cancer maybea very efficient method
for delivering a therapeutically effective insect cell compo-
sition to counteract the clinical disease. Similarly, chemo- or
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radiotherapy maybedirected to a particular, affected region
of the subject’s body. Alternatively, systemic delivery of
insect cell composition and/or the agent may be appropriate
in certain circumstances, for example, where extensive
metastasis has occurred. The skilled artisan will realize that
disruption of H5 cells, for example by freeze-thaw cycles,
inactivates the baculovirus without significantly affecting
the expressed therapeutic proteins.
In addition to combining insect cell composition-targeted
therapies with chemo- and radiotherapies, it also is contem-
plated that combination with gene therapies may be advan-
tageous. For example, simultaneous targeting of therapies
directed toward insect cell compositions and p53 maypro-
duce an improved anti-cancer treatment. Any other tumor-
related gene conceivably can be targeted in this manner, for
example, p21, Rb, APC, DCC. NF-1, NF-2, p16, FHIT,
WT-1, MEN-I, MEN-U, VHL, FCC, MCC, ras, myc, neu,
raf, erb,src, fms, jun,trk, ret, gsp, hst, bel and abl. cl 4.7 Kits
All the essential materials and reagents required for the
various aspects of the present invention may be assembled
together in a kit. When the components of the kit are
provided in one or more liquid solutions, the liquid solution
preferably is an aqueous solution, with a sterile aqueous
solution being particularly preferred. In the practice of the
present invention, such kit components may comprise iso-
lated insect cells. insect cells containing baculovirus or
insect cells containing baculovirus that have been geneti-
cally engineered to contain genes encoding therapeutic
proteins. In preferred embodiments, the therapeutic proteins
are expressed within the insect cell. Such insect cells may be
intact or lyophilized. In a preferred embodiment, the insect
cells are disrupted by freeze-thaw cycles or other methods
that disrupt the structurally integrity of the cell without
adversely affecting the protein constituents, including any
therapeutic protein(s) of interest.
For in vivo use, the instant compositions may be formu-
lated into a single or separate pharmaceutically acceptable
syringeable composition. In this case, the container means
may itself be an inhalant, syringe, pipette, eye dropper, or
other such like apparatus, from which the formulation may
be applied to an infected area of the body, such as the lungs,
injected into an animal, or even applied to and mixed with
the other components of the kit.
The components of the kit may also be provided in dried
or lyophilized forms. When reagents or components are
provided as a dried form, reconstitution generally is by the
addition of a suitable solvent. It is envisioned that the
solvent also may be provided in another container means.
The kits of the present invention also will typically
include a means for containing the vials in close confine-
ment for commercial sale such as, e.g., injection or blow-
molded plastic containers into which the desired vials are
retained. Irrespective of the number or type of containers,
the kits of the invention also may comprise, or be packaged
with, an instrument for assisting with the injection/
administration or placement of the ultimate complex com-
position within the body of an animal. Such an instrument
may be an inhalant, syringe, pipette, forceps, measured
spoon, eye dropper or any such medically approved delivery
vehicle. Additionally instructions for use of the kit compo-
nents is typically included.
5.0 EXAMPLES
The following examples are included to demonstrate
preferred embodiments of the invention. It should be appre-
ciated by those of skill in the art that the techniques
disclosed in the examples which follow represent techniques
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discovered by the inventor to function well in the practice of
the invention, and thus can be considered to constitute
preferred modesfor its practice. However, those of skill in
the art should, in light of the present disclosure, appreciate
that many changes can be madein the specific embodiments
which are disclosed andstill obtain a like or similar result
without departing from the spirit and scope of the invention.
5.1 Example 1
In Vitro Activation of Macrophages by H5 Cells
Infected with Baculovirus Encoding IFN-6
The H5insectcell line (Invitrogen, Sorrento, Calif.) used
in these examples was developed by the Boyce Thompson
Institute for Plant Research, Ithaca, N.Y. It was originated
from the ovarian cells of the cabbage looper, Trichoplusia ni.
This cell line doubles in less than 24 h, grows well in
monolayer, is adaptable to suspension cultures and serum-
free medium and provides 5- to 10-fold higher secreted
expression than Sf9 cells. The H5insectcellline is primarily
used for high expression of recombinant proteins.
A recombinant baculovirus encoding mouse interferon-f
(IFN-B) gene was developed by the inventors, with a titer of
about 5x10° PFU/ml. After infection by baculovirus-IFN-B,
H5 cells secreted high levels of IFN-$. To prepare the
baculovirus, the full coding region of the mouse IFN-B
cDNAwassubclonedinto the plasmid pxCMVthat contains
adenoviral genome to derive a shuttle vector pECIFN-£
(Graham and Prevec, 1991). The cDNA fragment was then
amplified by PCR using the pECIFN-B as template. The
restriction enzyme sites for Pstl and EcoRI were added to
the upper (SEQ ID NO:1) and lower (SEQ ID NO:2)
primers, respectively. After restrictive digestion with Pst1
and EcoRI, the PCR fragment that contained the mIFN-£
coding sequence was subcloned into the baculovirus vector
pBlue Bac2A (Invitrogen, San Diego, Calif.) to derive
pBac-mIFN-f that was verified by restriction mapping. The
pBac-mIFN-B was transfected into SF9 insect cells
(Invitrogen San Diego, Calif.) to generate a baculovirus
encoding mIFN-f (Bac-mIFN-B) according to the manufac-
turer’s instructions (Invitrogen, San Diego, Calif.). Produc-
tion of functional mIFN-f was assessed using a bioassay in
which IFN-6 and LPS activates macrophage to produce
nitric oxide (Dong et al., 1998). The stock Bac-mIFN-B
produced by SF9 cells was stored at 4° C.
5'-ATCTGCAGAGCCCTCTCCATCAACTA-3' (SEQ ID
NO:1)
5'-TTCCAAAACTGAAGAAGGATTCGAAG-3' (SEQ
ID NO:2)
For infection of insect cells with baculovirus, H5 insect
cells (Invitrogen, San Diego, Calif.) were plated into tissue
culture flasks at a density of 4x10* cells/em? in 0.15 ml of
serum free EXCELL 400 medium (JRH BioSciences,
Lenexa, Kans.). After overnight incubation at 28° C., the
cells were incubated with 2 plaque-forming units/cell of
Bac-mIFN-B for 36 hr. The culture medium was removed
and the infected cells were resuspended in phosphate buff-
ered saline (PBS) and used in the therapy experiments
described below.
An in vitro assay for macrophage activation was per-
formed according to Donget al. (1995). Macrophages were
exposed to either control medium, supernatant (1:20
dilution) from cultures of H5 insect cells alone or superna-
tant from cultures of H5 cells infected with baculovirus-
IFN-6, then challenged with lipopolysaccharide (LPS). As
shownin FIG. 1, macrophageactivation only occurred in the
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presence of H5 cells containing baculovirus-IFN-f. Thus,
production of the encoded IFN-f protein wassufficient to
cause macrophageactivation in vitro. This example further
demonstrated that the expressed IFN-f protein was secreted
into the supernatant by the baculovirus-infected H5 cells.
Activation of macrophagesalso was observed using soni-
cated cell lysates of H5 cells (FIG. 2A). Sonicated control
H5cells had no effect on macrophageactivation (FIG. 2B).
Astandard dose-response curve was observed for macroph-
age activation by IFN-6 (FIG. 2C). However, using soni-
cated cell lysates a maximum activation of macrophages was
observed at a dosage of 10* cells per well in 200 ul of
solution (FIG. 2A).
5.2 Example 2
In Vivo Tumor Regression Induced by H5 Cells
Infected with Baculovirus Encoding Interferon-6
C3H/HeN mice (n=10) were injected subcutaneously
(s.c.) with viable syngeneic UV-2237 M2fibrosarcomacells.
The UV-2237Mcell line (Raz et al., 1981) was derived from
spontaneous lung metastases produced by the UV2237
fibrosarcoma, which wasoriginally induced in a C3H/HeN
mouse by ultraviolet irradiation (Kripke, 1977). When the
tumors reached 5-6 mm in diameter (day 9 of the study),
1x10° untransfected H5 cells (H5) or 1x10° H5cells trans-
fected with baculovirus encoding IFN-B (H5-IFN-B) were
injected into the tumors. Subsequentto this single injection,
all tumors (n=10) injected with H5-IFN-f regressed,
whereas tumors injected with saline (control) or H5 cells did
not (FIG. 3). Although injection with H5 cells alone gener-
ally was notsufficient to promote tumor regression, in some
cases it caused a decrease in tumor growth rate compared to
the control tumors injected with saline (FIG. 3). This
example has been repeated at least 4 times, with similar
results observed each time. In several of these repetitions,
injection of tumors with H5-IFN-f cells was sufficient to
promote complete regression of the tumors (FIG. 4). A
typical time course for tumor regression is shown below in
Table 3.
TABLE 3
 
Regression of UV-2237M Subcutaneous Tumor Subsequent to a
Single Injection with H5 IFN-f Cells
Mean tumorsize (mm) +
Day Saline control H5 control H5 IFN-6
9 3.6 £17 3.9 £12 4.2 #12
16 5.6215 6.0 +1.0 5.6 #11
21 T7221 6.3414 47 £12
26 10.1 + 2.6 6.5 + 3.5 2.9 + 2.9
31 12.5 + 3.0 75248 2.0 # 1.1
35 14.8 + 2.7 8.7 + 5.67 1.9 + 10°
incidence 8/8 6/8 2/8
 
4UV-2237M cells (2 x 10°/mouse) were injected s.c. into C3H/HeN mice.
Nine days later, the mice were treated by intratumoral injection ofsaline,
HS, or H5-IFN.
Infect H5 cells with Bac-IFN: H5cells in T150 flasks were infected with
50 wl Bac-IFN for 24 h. The cells were harvested and used on treated
tumors.°UV-2237M2cells (2 x 10°) wereinjected s.c. into syngeneic C3H/HeN
female mice (10-12 wks of age). When the tumors reached the diameter
of 34 mm in diameter (day 9), the mice were randomized into 3 groups:
saline control, HS cells (1 x 10°) control, and HS mlFN-Bcells (1 x 10°),
that were injected once into the tumors. Tumor size was determined using
calipers.
5.3 Example 3
Lack of Survival of H5 Cells In Vivo
H5-IFN-£ cells were radiolabeled with !*°Iododeoxyuri-
dine. As shown in Table 4, radiolabeled cells survived in
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culture in vitro for 120 hr with no evidence of radiotoxicity.
In contrast, radiolabeled H5-IFN-B cells intravenously
injected into mice were eliminated within 48 h. These data
indicated that the regression of tumors did not require viable
H5-IFN-6 cells.
TABLE 4
 
Survival of [*7°I]IdUrd-labeled H5cells
injection site in vivo and in vitro
Input
HScells Input Left leg radio-
Time radioactivity radioactivity radioactivity activity
(h) Median Range (%) Median Range (%)
QO 11741 (41458, 100 12534 10012024)
1 4904 (4797, 43 6055 (5907, 485139 6563)
24 6898 (6371, 59 500 (330, 46944) 552)
48 8728 (8163, 74 16 (1, 19) 0.18935)72 8527 (8387, B 0 (0, 0) 0
8545)120 8680 (8439, 74 0 (0, 0) 08879)
 
5.4 Example 4
Eradication of Subcutaneous Tumors by
Lyophilized H5-IFN-6 Cells
C3H/HeN mice were injected s.c. with viable UV-2237
M2cells. After the tumors reached 4-5 mm in diameter,
groups of mice (n=10) were injected once into the tumors
with saline (untreated), 1x10° live H5-IFN-f cells, 1x10°
frozen-thawed (3 times) H5-IFN-cells, or 1x10° lyo-
philized H5-IFN-6 cells.
As shownin FIG.5, there was essentially no difference in
tumor regression induced by live, freeze-thawed (dead) or
lyophilized H5-IFN-6 cells. This result is significant for
potential therapeutic uses of compositions comprising insect
cells, as lyophilized or otherwise inactivated insect cells
would be advantageous for clinical use. subsequent
examples utilized injections of lyophilized H5-IFN-B cells.
5.5 Example 5
Treatment of Mice with H5-IFN-B Cells Induces
Systemic Immunity to the Same Tumor
C3H/HeN mice were injected s.c. with viable syngeneic
UV-2237 M2 fibrosarcoma cells. When the tumors reached
5-6 mm in diameter, the mice were given a single intratu-
moralinjection of saline (untreated), lyophilized preparation
of untransfected H5 cells (1x10°/dose), or lyophilized
preparation of H5-IFN-f cells (110°). All tumors injected
with H5-IFN-B cells regressed by day 25 of the study.
Mice cured bythis treatment (n=10) were challenged s.c.
with 5x10*,2x10°, or 5x10° viable UV-2237 M2 cells (n=5).
As shown in FIG. 6, none of the cured mice developed
tumors, whereas all of the control mice did.
This unexpected result is of great significance for thera-
peutic treatment of cancer. It demonstrates that within the
scope of the present invention, it is possible to immunize
mammals using the insect cell compositions described
herein, and to provide such mammals with immunity to
further challenge by the same tumor. In principle, injection
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of the claimed insect cell compositions into, for example, an
individual with lung cancer, followed by regression of the
tumor, should provide that individual with resistance to
future development of tumors of the same type. It is not
presently known how long such immunity might last.
However, methods of periodically boosting immunity
against a given disease-associated antigen are known in the
art and are within the scope of the present invention.
5.6 Example 6
Systemic Immunity is Tumor Specific
The resistance to the tumor challenge was determined to
be specific. Control C3H/HeN mice and C3H/HeN mice
cured of s.c. UV-2237M tumors by a single intratumoral
injection of lyophilized H5-IFN-B cells were challenged
subcutaneously with non-cross-reacting syngeneic K-1735
melanomacells. Normal (control) mice and mice cured of
UV-2237M tumorsall developed subcutaneous melanomas
(FIG.7). Thus, the systemic immunity induced by treatment
with H5-IFN-B cells does not extend to tumors of different
antigenicity.
Twoto three months after H5-IFN-6 induced regression
of UV-2237M tumors, “cured” mice and control normal
mice were rechallenged with different numbers of
UV-2237M cells or K-1735 melanoma cells. The results
presented in Table 5 demonstrate that UV-2237M cells at
5x10‘, 1x10°, or 2x10° cells/inoculum produced tumorsin
all control normal mice. In contrast, C3H/HeN micethat had
been cured of UC-2273M tumors wereresistant to rechal-
lenge with UV-2273M cells. The injection of 5x10“, 1x10°,
or 2x10° K-1735 melanoma cells/inoculum produced
tumors in all control normal and UV-2273M “cured” mice.
TABLE5
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immunogenicity. GM-CSF transduced tumorcells are being
used in various preparations of tumor cell vaccines. The
injection of GM-CSFat a site of vaccination (tumorcell
vaccine preparations) has been shownto increase immuno-
genicity. presumably by an effect on antigen-presenting
cells. These data suggest that GM-CSF can be used to
augment immune response.
H5insect cells infected with baculovirus encoding murine
GM-CSF may be admixed with tumorcells and injecteds.c.
or im. (intramuscularly) into mammals. The combination of
GM-CSFproducing insect cells plus tumorcells (antigen)
immunizes the mice against specific TAAs present on the
tumor cells. In this embodiment, insect cells producing
cytokines act as a universal adjuvant in a vaccine regimen.
This adjuvant may be used for treatment of cancer, AIDS,
influenza, and other diseases that are amenable to immune
system intervention. The insect cells expressing the cytokine
may be viable, frozen-thawed or lyophilized. The immuno-
genicity of the insect cell proteins, coupled with a cytokine
stimulates immunity against anotherprotein, such as a tumor
antigen, virus or bacterium.
All of the compositions and methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the compositions and methods andin the steps or
in the sequence of steps of the methods described herein
without departing from the concept, spirit and scope of the
invention. More specifically, it will be apparent that certain
agents which are both chemically and physiologically
related may be substituted for the agents described herein
while the same or similar results would be achieved. All
 
Eradication of subcutaneous UV-2273m tumors by direct
injection of H-5 IFN-f cells produces systemic immunity
Mice Tumorcells Incidence Size Incidence Size Incidence Size
Control UV-2237M 5/5 724219 5/5 8.9 + 0.6 5/5 8.9 +0.7
Control K-1735 5/5 6.9 + 4.0 5/5 6.8 + 3.0 5/5 8.4 +2.9
H-5 IFN-B UV-2237M 0/5 0/5 _— 0/5 _—
H-5 IFN-B K-1735 5/5 6.7 + 3.4 5/5 4.3 + 3.0 5/5 5.2 +2.9
Incidence = Numberof positive mice/Numberof injected mice.
Tumorsize = Diameter in mm + S.D.
5.7 Example 7
Immunohistochemistry of Regressing Tumors
Intratumoral injection of H5-IFN-f can recruit macroph-
ages (scavenger receptor positive cells) and CD-4 and CD-8
positive T cells (L3T4 and Lyt2 positive cells). The injection
and lymphoid infiltration associated with inhibition of tumor
cell proliferation was reflected in a decrease in proliferating
cell nuclear antigen (PCNA)positive cells and in an increase
in cells undergoing apoptosis (TUNELpositive cells) (FIG.
8). Thus, injection of H5-IFN-f is associated with activation
of the host immune system.
5.8 Example 8
Use of Insect Cells Producing Cytokines in
Prophylactic or Therapeutic Vaccines
Transduction of weak immunogenic tumorcells with the
GM-CSF gene has been shown to enhance antigenicity-
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such similar substitutes and modifications apparent to those
skilled in the art are deemedto be within the spirit, scope and
concept of the invention as defined by the appended claims.
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SEQUENCE LISTING
<160> NUMBER OF SEQ ID NOS: 2
<210> SEQ ID NO 1
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 1
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-continued
atctgcagag ccctctccat caacta 26
<210> SEQ ID NO 2
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<400> SEQUENCE: 2
ttccaaaact gaagaaggat tcgaag 26
What is claimed is: 15 5. The method of claim 1, wherein the effective amount of
1. A methodof treating a mammal having a solid tumor,
comprising:
a) providing a pharmaceutical composition comprising
insect cells containing a recombinant baculovirus vec-
tor encoding a $-interferon or GM-CSF, wherein said
B-interferon or GM-CSFis expressed in said cells; and
b) administering directly to said solid tumor a therapeu-
tically effective amount of said composition;
wherein said B-interferon or GM-CSF is present in an
unpurified form and wherein said administration is effective
to reduce or eliminate said solid tumor in said mammal.
2. The method of claim 1, wherein said administration
results in the immunization of said mammal against recur-
rence of said solid tumor.
3. The method of claim 1, wherein said composition is
injected directly into said tumor.
4. The method of claim 1, wherein the effective amount of
said composition is administered directly to said solid tumor
at least twice.
20
25
30
said composition is administered directly to said solid tumor
at least three times.
6. The method of claim 1, wherein said composition
comprises between about 10° and about 10” insectcells.
7. The method of claim 1, wherein said insect cells are
Spodoptera or Trichoplusia cells.
8. The method of claim 7, wherein said insect cells are
Spodoptera frugiperda cells.
9. The method of claim 7, wherein said insect cells are
Trichoplusia ni cells.
10. The method of claim 1, wherein said mammal is a
human subject.
11. The method of claim 1, wherein said insect cells are
inactivated prior to said administering step.
12. The method of claim 11, wherein said inactivation
occurs by subjecting said cells to freeze-thaw cycles.
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